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Abstract: Older adults with depression often present with signs and symptoms indicative of 
functional or cognitive impairment. These somatic symptoms make evaluating and treating 
depression in older adults more complex. Late life depression (LLD), depression in adults over 
the age of 65, is more frequently associated with cognitive changes. Cognitive impairment in 
LLD may be a result of the depressive disorder or an underlying dementing condition. Memory 
complaints are also common in older adults with depression. There is a wide range of cognitive 
impairment in LLD including decreased central processing speed, executive dysfunction, 
and impaired short-term memory. The etiology of cognitive impairment in LLD may include 
cerebrovascular disease, a signiﬁ cant risk factor for LLD, which likely interrupts key pathways 
between frontal white matter and subcortical structures important in mood regulation. Because 
depressive symptoms often coexist with dementia, it is important to determine the temporal 
relationship between depressive symptoms and cognitive change. If depressive symptoms 
pre-date the cognitive impairment and cognitive symptoms are mild and temporary, LLD is 
the likely etiology of the cognitive impairment. If cognitive changes appear prior to depressive 
symptoms and persist after LLD is successfully treated, an underlying dementia is more likely. 
Clinicians should be exclude common conditions such as thyroid disease which can contribute 
to depressive symptoms and cognitive impairment prior to treating LLD. Both antidepressants 
and psychotherapy can be effective in treating LLD. Subsequent evaluations following treatment 
should also reassess cognition. 
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Introduction
Depression in older adults is a serious illness and may lead to impaired physical function, 
increased mortality, and unwarranted use of health care resources. Late life depression 
(LLD), depression occurring in patients over age 65, remains under-diagnosed and 
under-treated. The prevalence of LLD varies depending on the population studied, 
affecting up to 9% of community dwelling elderly but 25% of institutionalized elderly 
and those recently hospitalized.1,2 Compared to adults with depression earlier in life 
(early onset depression), patients with late-onset depression (ﬁ rst episode after age 65) 
are less likely to have a family history of depression and are likely to have signiﬁ cant 
comorbidities, especially cardiovascular diseases. Consequently, environmental factors 
and lifestyle factors may be associated with the development of LLD.
Patients with LLD often present with cognitive complaints or cognitive deﬁ cits. 
These cognitive changes may occur as a consequence of depression or may indicate a 
coexisting condition such as Alzheimer’s disease or Parkinson’s disease. Establishing 
whether depression is the primary cause of cognitive change or whether a concomitant 
dementing illness exists is important in the management of the disease. Since more 
than 75% of care for LLD is provided by non-psychiatrists, it is imperative that primary 
care providers are able to diagnosis LLD and distinguish it from other diseases which 
can present with similar symptoms.
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Pathophysiology
LLD is thought to be pathophysiologically different from 
depression in young adults as it is often associated with 
comorbid illnesses. Risk factors for LLD include stressors 
such as living alone, chronic pain, and comorbid illnesses 
such as cardiovascular disease. See Table 1 for additional 
risk factors.
Over the last two decades, studies have identified 
important biological and cognitive correlates of depression 
in late life. Among these are associations with morphologic 
abnormalities in key brain structures and neuropsychological 
abnormalities in executive function and memory.3–5 
Several studies have found a strong association between 
cerebrovascular risk factors and LLD.6,7 In some individuals, 
vascular disease may contribute to the development of a late 
life depression syndrome by interrupting the connections 
between frontal white matter pathways and subcortical 
structures (such as basal ganglia) involved in mood.8–10
The term vascular depression has emerged from 
imaging findings of white matter hyperintensities 
associated with LLD. Studies have found that patients 
with LLD and structural magnetic resonance imaging 
(MRI) evidence of cerebrovascular disease have greater 
neuropsychological impairment on testing.11,12 We found 
a wide range of disruption of cognitive functioning in 
LLD, in particular, processing speed was a core cognitive 
deﬁ cit.13 It is hypothesized that cerebrovascular ischemia 
disrupts brain circuitry and results in depression as well 
as neuropsychological impairment. Clinical factors that 
might be linked to worse neuropsychological performance 
in LLD, include depression severity, comorbid anxiety, 
vegetative symptoms, number of prior episodes, age and 
late age of depression onset.14,15 Cognitive impairment 
in LLD has also been shown to be greater in late-onset 
depression.16
Diagnosis
Although the diagnostic criteria for LLD are the same as 
depression in younger adults, patients with LLD often 
present with more somatic symptoms. Making a diagnosis 
of LLD can be difﬁ cult for many reasons including more 
subtle presentations in older adults, coexisting medical 
illnesses, and reluctance to self-report symptoms. In addition 
to the obvious signs of depression, patients with LLD may 
have nonspeciﬁ c symptoms which may be confused with 
physical illness such as psychomotor slowing, fatigue, and 
increased pain.
Additionally, many clinicians use the term ‘depression’ 
not only in reference to a major depressive episode (MDE), 
but also to describe a symptom or other nonspeciﬁ c syndrome. 
The diagnostic criteria for depression/MDE and special 
considerations in older adults are presented in Table 2.
Table 1 Risk factors for late life depression28,29
Gender (Women are more likely than men)
Marital status (widowed, divorced, single)
Social isolation
Alcohol use
Medications
• Chronic benzodiazepine use
• Narcotics
• Antihypertensives (beta blockers)
• Interferon alpha
Death of spouse or close loved-one
Severe and chronic pain
Medical illnesses
• Cancer
• Hypothyroidism
• Stroke
• Dementing Illnesses- (Alzheimer’s disease, Parkinson’s disease)
• Myocardial Infarction
• Hip fracture
• Coronary artery bypass surgery
Table 2 DSM-IV diagnostic criteria for episode of major depression 
and special considerations in late life depression
Five or more of the following 9 symptoms present nearly every day for at 
least 2 weeks (at least one symptom being depressed mood or diminished 
interest or pleasure):
 1. Depressed mood
 2. Markedly diminished interest or pleasure in almost all activities
 3. Fatigue or loss of energy
 4. Feelings of worthlessness or excessive or inappropriate guilt
 5. Clinically signifi cant weight loss or weight gain or decrease in appetite
 6. Insomnia or hypersomnia
 7. Observable psychomotor agitation or retardation
 8. Diminished ability to think or concentrate, or indecisiveness
 9. Recurrent thoughts of death or suicidal ideation
Special considerations for older adults with depressive symptoms
 • Coexisting memory complaints are common
 • Many older adults believe depression is normal with aging
 • Psychosocial risk factors for depression are common
 •  Symptoms from chronic medical illnesses (fatigue, weight loss) may 
overlap with depressive symptoms
 • Older men have highest rates of suicide
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Diagnosing LLD can be especially challenging in those 
with cognitive impairment. Whether cognitive changes in 
the setting of LLD signals a coexisting illness or is simply 
an effect of the depression is a complex question. Some 
older adults present with cognitive complaints yet meet 
criteria for depression; similarly, older adults may report 
depressed mood but are actually demented. Although 
pseudodementia can be caused by LLD, pseudodementia 
is relatively uncommon and depression commonly coexists 
with dementing illnesses including 40% of Parkinson’s 
disease, 20%–30% of Alzheimer’s disease, and 30%–60% 
of stroke patients.
The evaluation of depressive symptoms and cognitive 
changes must include a complete history and physical 
with a detailed neurological exam to determine whether 
focal deﬁ cits or parkinsonism are present. Laboratory tests 
for thyroid disease, B12 deficiency, anemia, and renal 
impairment should be performed to exclude an underlying 
medical illness. A brief interview with the patient’s spouse, 
adult child, other relative or friend is extremely helpful 
in determining whether the patient’s symptoms are most 
likely depression or an underlying dementia.17 If depressive 
symptoms began prior to or concurrent with cognitive 
changes, depression may be more likely. If cognitive changes 
are more consistent and preceded the depressive symptoms, 
more consideration of a dementing illness is warranted.
Following the history and physical, depressive 
symptoms should be assessed using a screening tool. 
Several screening tools have been successfully used to 
identify LLD. These screens can help detect depressive 
symptoms but they should not be used independently to 
diagnose LLD. Patients who screen positive should be 
further interviewed to determine whether diagnostic criteria 
for depression are met.
Although there are numerous screening instruments, 
it is important to identify screening tools that have 
been validated and are easy to administer and interpret. 
The Geriatric Depression Scale (GDS), Patient Health 
Questionnaire-9 (PHQ-9), and the Center for Epidemiologic 
Studies Depression Scale (CES-D) are all useful for 
identifying depressive symptoms in the elderly.
The GDS has been studied in multiple settings and was 
designed speciﬁ cally for older adults.18 The ﬁ fteen-item 
version has demonstrated good operating characteristics 
across the full spectrum of elderly populations. Five or more 
depressive symptoms suggest the diagnosis of depression. 
The instrument can be self administered or given by the 
clinician/staff.
The PHQ-9 was developed speciﬁ cally for use in primary 
care settings and has demonstrated validity and reliability.19 
It encompasses all nine DSM-IV criteria for major depression 
and has been shown to be a reliable measure of depression 
treatment outcomes in a large study of older adults. The full 
PHQ-9 is shown in Figure 1. The tool can also be used to 
assess response to treatment in individual patient care.
The CES-D is commonly used in primary care settings 
for the assessment of depressive symptoms.20 Although it 
has been used in older adults, the instrument was developed 
for research not for the clinical setting so individual scores 
must be interpreted with caution.
Assessment of cognitive performance using a tool such as 
the Mini-Mental State Exam, the Short Blessed Test, or other 
cognitive screening tool should be performed. While these 
screening tools alone should not be used to determine whether 
the patient is cognitively impaired, they may be useful in 
following cognitive performance during and after treatment 
of depression. If cognitive impairment persists after depres-
sive symptoms improve, additional evaluations to exclude 
underlying or coexisting dementia should be pursued. This 
evaluation should include brain imaging to exclude stroke, 
tumor, and normal pressure hydrocephalus.
Addressing psychosocial risk factors
Psychosocial risk factors for LLD are common and many 
older adults with depression often have more than one risk 
factor. Common psychosocial factors in LLD include loss 
of function or physical disability, bereavement, caregiver 
stress, lack of social support, and change in societal roles (ie, 
retirement).21 It is important to identify these risk factors and 
determine their effect on LLD. Unfortunately, there are no 
existing tools that accurately predict risk of LLD based on 
psychosocial risk factors. The clinician should ask patients 
with depression whether recent life events are contributing 
to depressive symptoms as patients with signiﬁ cant psycho-
social risk factors may beneﬁ t more from psychotherapy.
Treatment
After the careful diagnosis of LLD, the initial treatment 
of choice in the primary care setting is the use of 
antidepressant medications. There is also good evidence 
for the efﬁ cacy of psychotherapy as a treatment option;22 
however, this requires a specialist referral. The overarching 
principal, as in other areas of geriatric medicine, is to use 
a low starting dose and to slowly increase the dose as 
necessary. It is usual to start treatment with one half of 
the younger adult starting dose and to make subsequent 
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Figure 1 PHQ-9 for the assessment of depression.
Name ______________________ Date _________
Over the last 2 weeks, how often have you been 
bothered by any of the following problems?
Not at 
all
Several
days
More
than half 
the days
Nearly
every day
1. Little interest or pleasure in doing things 0 1 2 3
2. Feeling down, depressed, or hopeless 0 1 2 3
3. Trouble falling or staying asleep, or sleeping too 
much
0 1 2 3
4. Feeling tired or having little energy 0 1 2 3
5. Poor appetite or overeating 0 1 2 3
6. Feeling bad about yourself—or that you are a 
failure or have let yourself or your family down
0 1 2 3
7. Trouble concentrating on things, such as reading 
the newspaper or watching television
0 1 2 3
8. Moving or speaking so slowly that other people
could have noticed? Or the opposite—being so fidgety 
or restless that you have been moving around a lot 
more than usual
0 1 2 3
9. Thoughts that you would be better off dead or of 
hurting yourself in some way
0 1 2 3
(For office coding: Total Score  ____ = ____ + ____ + ____)
If you checked off any problems, how difficult have these problems made it for you to do your 
work, take care of things at home, or get along with other people?
Not difficult at all Somewhat difficult Very difficult Extremely difficult
□ □ □ □
Scoring—add all checked boxes on PHQ-9.
Total Score Depression Severity
0–4 None
5–9 Mild depression
10–14 Moderate depression
15–19 Moderately severe depression
20–27 Severe depression
From the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME-MD
PHQ). PHQ-9 © 1999 Pfizer Inc. All rights reserved. Reproduced with permission from Pfizer Inc.
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titrations in small dose intervals. Selective serotonin 
reuptake inhibitors (SSRIs) are the most commonly used 
ﬁ rst line treatment for depression including LLD as they 
have relatively low toxicity and high tolerability.23,24 Of 
the SSRIs, citalopram was used in a large NIH funded 
multi-center trial, the STAR*D trial, for the treatment 
of depression that included patients with late life depres-
sion.24 Citalopram was chosen for its once a day dosing, 
lack of discontinuation side-effects and low potential for 
drug-drug interaction, all attractive characteristics in LLD. 
Other choices include escitalopram with a similar proﬁ le 
as citalopram and sertraline (favorable proﬁ le at low dose) 
amongst other SSRIs (Table 3). The newer generation of 
antidepressants has a more diverse mechanism of action 
than the selective serotonin inhibition. These can be used 
as ﬁ rst line treatment, although the data supporting its 
use in LLD is limited (Table 3). The older antidepressant 
medications include the tricyclic antidepressants such 
as desipramine and the monoamine oxidase inhibitors 
such as selegiline have limited use in the elderly. These 
medications have signiﬁ cant side effect liability and are 
best prescribed and monitored by a psychiatrist.
Inadequate trial duration and suboptimal dosing are 
the two most common reasons for low treatment response. 
Adequate trial duration is at least 8 weeks of treatment 
and the dose should be carefully increased to the upper 
dosage range, as tolerated, if patient shows no response. 
Also, SSRI and other antidepressant medications take 
at least two weeks before any improvement is noticed, 
with optimal reduction in symptoms taking as long as 
8–12 weeks. It is therefore prudent to wait for a minimum 
of two weeks before dose increases. It is best to discuss 
this lag period with the patient and their caregivers in the 
process of obtaining informed consent; also, the concern 
that the SSRI group of medications may cause increased 
suicidal ideations should be made explicit. All antidepres-
sants can cause GI symptoms during the initial treatment 
period and are usually self limiting; further reduction of 
dosage or a switch to another agent can remedy this. Sexual 
dysfunction may be another of the side effects that should 
be discussed. Table 4 includes a list of common side effects 
of some antidepressants.
Along with the medication, it is important to assess the 
adequacy of social support, any impediment to medication 
Table 3 Select antidepressants
Antidepressant Initial dose Dosage range Pharmacokinetics Comments
SSRI:
1.  Citalopram 
(Celexa)
10 mg 20–40 mg Weak inhibitor of CYP450 
2D6
Well tolerated. Tramadol may 
increase risk of seizure
2.  Escitalopram 
(Lexapro)
5 mg 10–20 mg No signifi cant action on 
CYP450
Well tolerated. Caution if history of 
seizure
3.  Sertraline 
(Zoloft)
25 mg 50–200 mg Inhibits CYP450 2D6 and 
3A4 (weakly at low doses)
Caution with use of HMG CoA 
reductase inhibitors. Tramadol, 
Alprazolam, Thioridazine
4.  Fluoxetine 
(Prozac)
5 mg 10–40 mg Inhibits CYP450 2D6 and 
3A4
Long half life (2 weeks). Other 
cautions as for sertraline
5.  Paroxetine 
(Paxil) 10 mg 10–40 mg Inhibits CYP450 2D6 Caution with thioridazine, drugs 
with anticholinergic properties and 
theophylline
Others:
6.  Bupropion SR 
(Wellbutrin)
100 mg 100–400 mg Inhibits CYP450 2D6 Increases risk for seizure. Caution 
with levodopa and amantadine
7.  Venlafaxine XR 
(Effexor XR)
37.5 mg 75–225 mg No signifi cant action on 
CYP450
Increased BP that is dose dependent. 
SIADH, Hyponatremia. Do NOT use 
in uncontrolled glaucoma
8.  Duloxetine 
(Cymbalta)
20 mg 40–60 mg Inhibits CYP450 2D6 and 
1A2
Monitor BP as it may increase. Do 
NOT use in uncontrolled glaucoma 
or with thioridazine
9. Mirtazapine 
(Remeron)
7.5 mg 15–45 mg No signifi cant action on 
CYP450
May increase cholesterol, cause 
photosensitivity and rarely lower 
WBC count.
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compliance and other illnesses that may adversely impact 
depression. Interventions to improve social support may 
include educating the family about depression and the need 
for more close monitoring and encouragement to attend 
spiritual activities. Compliance with medication may be 
enhanced with the use of a pillbox and involvement of a 
caregiver. Optimal treatment of patients’ co-morbid medical 
illnesses will contribute to patients’ improved sense of 
well-being and mental health.
When to refer
Severity
The severity of depression will determine the aggressiveness 
of the treatment approach. Any suicidal ideation, weight 
loss due to decreased food intake, low ﬂ uid intake, and 
psychomotor retardation alongside intense low mood will 
require a more aggressive management strategy. Such severe 
depression will warrant an aggressive treatment strategy and 
may require the use of electroconvulsive therapy (ECT), 
combination antidepressant therapy, use of tricyclics or 
monoamine oxidase inhibitors, all requiring prompt referral 
to a psychiatrist. The psychiatrist may treat this patient 
alongside the primary care physician or serve as a consultant 
who does crisis intervention. The primary care provider may 
continue managing the patient’s depression once the severity 
of depression has lessened and patient has achieved response 
or preferably, remission.
Psychotherapy
The efﬁ cacy of psychotherapy is well supported by litera-
ture for treatment of mild to moderate depression.22 Patients 
who wish to avoid or delay antidepressants and those with 
signiﬁ cant psychosocial risk factors may be good candidates for 
psychotherapy. Both cognitive behavioral therapy (CBT) and 
interpersonal psychotherapy (IPT) are effective in older adults 
with depression including those with cognitive impairment. 
CBT focuses on modifying everyday thoughts and behaviors 
by positively influencing emotions. Distorted thinking 
is recognized and replaced with more realistic substitute 
ideas. In IPT, education about depression is provided and 
interpersonal events that could be associated with depressive 
symptoms are explored. Possible solutions are also pursued. 
A licensed mental health therapist will provide appropriate 
psychotherapy.
Failure of fi rst-line antidepressant 
medication
If patient does not respond to the ﬁ rst-line antidepressant 
medication treatment, it may be best to obtain a psychiatrist 
intervention. The treatment options at this stage include use 
of augmentation with another antidepressant/psychotherapy 
or switching to another agent. This becomes a complex issue 
and a specialist will be able to offer a larger spectrum of 
treatment options. Failure of antidepressant therapy may also 
indicate an underlying cognitive impairment.
Recurrent or relapsing depression
Longitudinal studies indicate that a signiﬁ cant number of 
patients are at a high risk of relapse even after successful 
treatment.25 Biological and social factors both affect an 
elderly individual’s long-term course of depression, both in 
the acute phase and longer term. Although there is signiﬁ cant 
individual variability in disease course in patients with LLD, 
a greater number of previous depressive episodes increases 
the risk of future relapse and decreases time to relapse.26,27
Depressed elderly individuals who do not respond 
to ﬁ rst-line antidepressant therapy, who exhibit greater 
residual depressive symptoms, or who require a longer 
time to respond to treatment are at higher risk of relapse. 
Discontinuation of maintenance antidepressant therapy in 
elderly individuals also carries a high risk. Accordingly, a 
referral to a psychiatrist may improve treatment outcomes.
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